Background. In patients with peptic ulcer bleeding, acid can enhance platelet disaggregation and cause lysis of the clot. Omeprazole, a potent acid suppressor, may be helpful in reducing their rebleeding rate. Methods. Between March and October 1994, 40 patients with a non-bleeding, visible vessel (NBVV) at ulcer bases were enrolled for study. They were randomized into four groups. Group I (n = 10) patients received cimetidine 300 mg intravenously (i.v.) q6h; Group II (n = 10) patients received heater probe thermocoagulation therapy and cimetidine 300 mg i.v. q6h; Group III (n = 10) patients received omeprazole 40 mg intravenous bolus initially followed by 40 mg i.v. qd and Group IV (n = 10) patients received omeprazole 40 mg intravenous bolus initially followed by 40 mg i.v. q12h. Endoscopic examination was done for follow-up, daily, for 1-3 days. Results. Preliminary results showed that the age, initial hemoglobin, ulcer size as well as NBVV size in Groups I-IV were not significantly different (p <0.05). The rebleeding rates were 40% in Group I, 20% in Group II, 20% in Group III and 0% in Group IV. (p <0.05 when Group IV is compared with Group I). Conclusions. Intravenous omeprazole 40 mg given q12h can reduce the rebleeding rate of patients with a NBVV.
|Number of pages||7|
|Journal||Chinese Medical Journal (Taipei)|
|Publication status||Published - Feb 1996|
- non-bleeding visible vessel
- peptic ulcer
ASJC Scopus subject areas